Skip to content
Science
Pipeline
Clinical Trials
Medicines
Culture & Careers

Pipeline

Novel oncolytic immunotherapies built on our proprietary RPx platform

RPx, a next-generation HSV-1-based oncolytic immunotherapy platform, powers our pipeline of novel therapies being studied across a broad range of cancer indications.

Commercial Products

TUDRIQEV

vusolimogene odeparepvec
engineered HSV backbone, GM-CSF, GALV-GP R-
Advanced Melanoma
TUDRIQEV in Combination with Nivolumab is indicated for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
Trial
IGNYTE
Phase 1
Phase 2
Phase 3
Commercial

Clinical Pipeline

RP1

vusolimogene oderparepvec
engineered HSV backbone, GM-CSF, GALV-GP R-
Trial
IGNYTE-3
Phase 1
Phase 2
Phase 3
Commercial
  • IGNYTE‑3 confirmatory trial in advanced melanoma underway and currently enrolling.
Trial
ARTACUS
Phase 1
Phase 2
Phase 3
Commercial
  • The ARTACUS trial is evaluating RP1 as monotherapy in patients with skin cancer who have received an organ transplant.

RP2

Engineered HSV backbone, GM-CSF, GALV-GP R-, anti-CTLA-4
Trial
REVEAL study
Phase 1
Phase 2
Phase 3
Commercial
  • Randomized, open-label Phase 2/3 clinical trial (RP2-202) studying RP2 in combination with nivolumab in metastatic uveal melanoma is currently enrolling.
Trial
RP2-003 currently enrolling
Phase 1
Phase 2
Phase 3
Commercial
  • Phase 2 study evaluating RP2 in combination with 1st or 2nd line therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
  • Clinical trial collaboration and supply agreement with Roche for atezolizumab and bevacizumab supply – full rights retained by Replimune.

Investigating new treatments for cancer

Replimune is currently recruiting patients to participate in clinical trials in several different types of cancer to find out if new treatments are safe and provide better outcomes than the existing standard of care. 

Clinical Trials